Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aplastic Anemia
Third course of ATG for aplastic anemia an option only for previous responders
June 17th, 2005
A third course of antithymocyte globulin (ATG) for aplastic anemia is an option only for previous responders. According to a study from England, "This retrospective study evaluated the outcome of 18 patients with aplastic anemia treated with a third course of antithymocyte globulin-containing immunosuppressive therapy (IST). Of the 18 patients, 7 had responded to 1 of the previous courses of ATG and 11 were refractory to both the previous courses." "Self-limiting grade {{>=}} 3 liver toxicity was observed in three patients. Two patients had to discontinue ATG because of severe systemic side effects. The incidence and manifestations of serum...
Source: Drug Week (2005-06-17)
|
